Changes in hepatic triglyceride content may be more pronounced in cats with hepatic pathology (e.g., lipidosis), and future studies are needed to determine if activation of the FGF21 pathway could be used to decrease hepatic triglyceride in more severely affected cats. The gene discussed is FGF21; the disease is lysosomal lipid storage disorder.